Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials

Radiotherapy and Oncology

Volumn 109, Issue 2, 2013, Pages 217-221

  King, Christopher R ^a   Freeman, Debra ^b   Kaplan, Irving ^b   Fuller, Donald ^c   Bolzicco, Giampaolo ^d   Collins, Sean ^e   Meier, Robert ^f   Wang, Jason ^a   Kupelian, Patrick ^a   Steinberg, Michael ^a   Katz, Alan ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Naples Radiation Oncology ^*  (United States)

^c Radiosurgery Medical Group   (United States)

^d SAN BORTOLO HOSPITAL   (Italy)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SWEDISH MEDICAL CENTER   (United States)

^g Flushing Radiation Oncology   (United States)

Author keywords

Hypo fractionation; Prostate cancer; PSA; Stereotactic body radiotherapy

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CYBERKNIFE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; RISK FACTOR; SHORT COURSE THERAPY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; TREATMENT FAILURE;

HYPO-FRACTIONATION; PROSTATE CANCER; PSA; STEREOTACTIC BODY RADIOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOSURGERY; SURVIVAL RATE;

EID: 84889590915     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.08.030     Document Type: Article

References (21)

1. R.W. Lloyd-Davies, C.D. Collins, and A.V. Swan Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984) Urology 36 1990 107 111
2. P.A. Kupelian, T.R. Willoughby, and C.A. Reddy Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430
3. E.E. Yeoh, R.J. Botten, and J. Butters Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial Int J Radiat Oncol Biol Phys 81 2011 1271 1278
4. G. Arcangeli, J. Fowler, and S. Gomellini Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 79 2011 1013 1021
5. H. Lukka, C. Hayter, and J.A. Julian Randomized trial comparing two fractionation schedules for patients with localized prostate cancer J Clin Oncol 23 2005 6132 6138
6. J.E. Livsey, R.A. Cowan, and J.P. Wylie Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis Int J Radiat Oncol Biol Phys 57 2003 1254 1259
7. M. Lock, L. Best, and E. Wong A phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer Int J Radiat Oncol Biol Phys 80 2011 1306 1315
8. J.M. Martin, T. Rosewall, and A. Bayley Phase II trial of hypofractionated image-guided intensity modulated radiotherapy for localized prostate adenocarcinoma Int J Radiat Oncol Biol Phys 69 2007 1084 1089
9. D. Dearnaley, I. Syndikus, and G. Sumo Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial Lancet Oncol 13 2012 43 54
10. J.H. Coote, J.P. Wylie, and R.A. Cowan Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity Int J Radiat Oncol Biol Phys 74 2009 1121 1127
11. B.L. Madsen, R.A. Hsi, and H.T. Pham Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized prostate disease: first clinical trial results Int J Radiat Oncol Biol Phys 67 2007 1099 1105
12. C.R. King, J.D. Brooks, H. Gill, and J.C. Presti Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer Int J Radiat Oncol Biol Phys 82 2012 877 882
13. D.B. Fuller, J. Naitoh, C. Lee, S. Hardy, and H. Jin Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations Int J Radiat Oncol Biol Phys 70 2008 1588 1597
14. A.J. Katz, M. Santoro, R. Ashley, F. Diblasio, and M. Witten Stereotactic body radiotherapy for organ-confined prostate cancer BMC Urol 10 2010 1
15. S.M. McBride, D.S. Wong, and J.J. Dombrowski Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial Cancer 118 2012 3681 3690
16. G. Bolzicco, M.S. Favretto, and E. Scremin Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results Technol Cancer Res Treat 9 2010 473 477
17. J.L. Friedland, D.E. Freeman, M.E. Masterson-McGary, and D.M. Spellberg Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer Technol Cancer Res Treat 8 2009 387 392
18. T.P. Boike, Y. Lotan, and L.C. Cho Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer J Clin Oncol 29 2011 2020 2026
19. A. Dasu, and I. Toma-Dasu Prostate alpha/beta revisited - an analysis of clinical results from 14,168 patients Acta Oncol 51 2012 963 974
20. M.S. Katz, J.A. Efstathiou, and A.V. D'Amico The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer BJU Int 105 2010 1417 1422
21. C.R. King, S. Collins, and D. Fuller Health related quality of life after stereotactic body radiotherapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials Int J Radiat Oncol Biol Phys 2013 (submitted)